Outcome of patients receiving radiation for cancer of the esophagus: Results of the 1992-1994 patterns of care study

被引:122
作者
Coia, LR
Minsky, BD
Berkey, BA
John, MJ
Haller, D
Landry, J
Pisansky, TM
Willett, CG
Hoffman, JP
Owen, JB
Hanks, GE
机构
[1] Community Med Ctr, Dept Radiat Oncol, Toms River, NJ 08755 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA
[3] Univ Penn, Med Ctr, Amer Coll Radiol, Philadelphia, PA 19104 USA
[4] Fox Chase Canc Ctr, Dept Surg Oncol, Philadelphia, PA 19111 USA
[5] Fox Chase Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19111 USA
[6] Canc Ctr St Agnes, Radiat Oncol Serv, Fresno, CA USA
[7] Emory Univ, Dept Radiat Oncol, Atlanta, GA 30322 USA
[8] Mayo Clin & Mayo Fdn, Div Radiat Oncol, Rochester, MN 55905 USA
[9] Cox Canc Ctr, Dept Radiat Med, Boston, MA USA
关键词
D O I
10.1200/JCO.2000.18.3.455
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: A patterns of Care Study examined the records of patients with esophageal cancer (EC) treated with radiation in 1992 through 1994 to determine the national practice processes of care and outcomes and to compare the results with those of clinical trials. Patients and Methods: A national survey of 63 institutions was conducted using two-stage cluster sampling, and specific information was collected on 400 patients with squamous cell (62%) or adenocarcinoma (37%) of the thoracic esophagus who received radiation therapy (RT) as part of primary or adjuvant treatment. Patients were staged according to a modified 1983 American Joint Committee on Cancer staging system. Fifteen percent of patients had clinical stage (CS) I disease, 40% had CS II disease, and 30% had CS III disease. Twenty-six percent of patients underwent esophagectomy. Seventy-five percent of patients received chemotherapy; 84% of these received concurrent chemotherapy and radiation (CRT). Results: Significant variables for overall survival in multivariate analysis include the use of esophagectomy (risk ratio [RR] = 0.62), the use of chemotherapy (RR = 0.63), Karnofsky performance status (KPS) greater than 80 (RR = 0.61), CS I or II disease (RR = 0.66), and facility type (RR = 0.72). Age, sex, and histology were not significant, Preoperative CRT resulted in a nonsignificantly higher a-year survival rate compared with definitive CRT alone (63% v 39%; P = .11), whereas 2-year survival by planned treatment rather than treatment given was 47.7% for preoperative CRT and 35.4% for definitive CRT (P = .23). Definitive CRT compared with definitive PT alone resulted in significantly higher 2-year survival (39% v 20.6%; P = .027) and lower 5-year local regional failure (30% v 57.9%; P = .0031). Conclusion: This study confirms the value of CRT in EC treatment. It indicates that the results obtained in practice settings nationwide are similar to those obtained in clinical trials and that KPS and the 1983 clinical staging system are useful prognostic indicators. The suggested value of esophagectomy and superiority of preoperative CRT over CRT alone in this study should be tested in a randomized trial. J Clin Oncol 18:455-462. (C) 2000 by American Society of Clinical Oncology.
引用
收藏
页码:455 / 462
页数:8
相关论文
共 21 条
  • [1] MANAGEMENT OF ADENOCARCINOMA OF THE ESOPHAGUS WITH CHEMORADIATION ALONE OR CHEMORADIATION FOLLOWED BY ESOPHAGECTOMY - RESULTS OF SEQUENTIAL NONRANDOMIZED PHASE-II STUDIES
    ALGAN, O
    COIA, LR
    KELLER, SM
    ENGSTROM, PF
    WEINER, LM
    SCHULTHEISS, TE
    HANKS, GE
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 32 (03): : 753 - 761
  • [2] Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: An intergroup study
    AlSarraf, M
    Martz, K
    Herskovic, A
    Leichman, L
    Brindle, JS
    Vaitkevicius, VK
    Cooper, J
    Byhardt, R
    Davis, L
    Emami, B
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) : 277 - 284
  • [3] RISING INCIDENCE OF ADENOCARCINOMA OF THE ESOPHAGUS AND GASTRIC CARDIA
    BLOT, WJ
    DEVESA, SS
    KNELLER, RW
    FRAUMENI, JF
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (10): : 1287 - 1289
  • [4] COMBINED-MODALITY THERAPY FOR ESOPHAGEAL-CARCINOMA - PRELIMINARY-RESULTS FROM A LARGE AUSTRALASIAN MULTICENTER STUDY
    BURMEISTER, BH
    DENHAM, JW
    OBRIEN, M
    JAMIESON, GG
    GILL, PG
    DEVITT, P
    YEOH, E
    HAMILTON, CS
    ACKLAND, SP
    LAMB, DS
    SPRY, NA
    JOSEPH, DJ
    ATKINSON, C
    WALKER, QJ
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 32 (04): : 997 - 1006
  • [5] Coia, 1994, Semin Radiat Oncol, V4, P157, DOI 10.1016/S1053-4296(05)80063-3
  • [6] Coia L R, 1998, Radiat Med, V16, P321
  • [7] Daly JM, 1996, CANCER, V78, P1820, DOI 10.1002/(SICI)1097-0142(19961015)78:8<1820::AID-CNCR25>3.0.CO
  • [8] 2-Z
  • [9] Factors influencing outcome following radio-chemotherapy for oesophageal cancer
    Denham, JW
    Burmeister, BH
    Lamb, DS
    Spry, NA
    Joseph, DJ
    Hamilton, CS
    Yeoh, E
    OBrien, P
    Walker, QJ
    [J]. RADIOTHERAPY AND ONCOLOGY, 1996, 40 (01) : 31 - 43
  • [10] CONCURRENT CHEMOTHERAPY AND RADIATION-THERAPY FOLLOWED BY TRANSHIATAL ESOPHAGECTOMY FOR LOCAL-REGIONAL CANCER OF THE ESOPHAGUS
    FORASTIERE, AA
    ORRINGER, MB
    PEREZTAMAYO, C
    URBA, SG
    HUSTED, S
    TAKASUGI, BJ
    ZAHURAK, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (01) : 119 - 127